Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 1
1965 1
1966 5
1967 7
1968 5
1969 8
1970 14
1971 19
1972 19
1973 10
1974 25
1975 53
1976 47
1977 53
1978 69
1979 50
1980 51
1981 53
1982 41
1983 52
1984 44
1985 55
1986 68
1987 51
1988 48
1989 64
1990 57
1991 86
1992 62
1993 73
1994 62
1995 85
1996 76
1997 75
1998 73
1999 82
2000 72
2001 94
2002 76
2003 91
2004 85
2005 104
2006 104
2007 106
2008 109
2009 152
2010 146
2011 159
2012 171
2013 193
2014 253
2015 216
2016 197
2017 253
2018 219
2019 223
2020 252
2021 237
2022 231
2023 180
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

5,136 results

Results by year

Filters applied: . Clear all
Page 1
Advancing therapy for osteosarcoma.
Gill J, Gorlick R. Gill J, et al. Nat Rev Clin Oncol. 2021 Oct;18(10):609-624. doi: 10.1038/s41571-021-00519-8. Epub 2021 Jun 15. Nat Rev Clin Oncol. 2021. PMID: 34131316 Review.
Improving the survival of patients with osteosarcoma has long proved challenging, although the treatment of this disease is on the precipice of advancement. ...In addition, trial designs will increasingly consider the genetic background of the tumour through biomark …
Improving the survival of patients with osteosarcoma has long proved challenging, although the treatment of this disease is on the pr …
Future Directions in the Treatment of Osteosarcoma.
Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Smrke A, et al. Cells. 2021 Jan 15;10(1):172. doi: 10.3390/cells10010172. Cells. 2021. PMID: 33467756 Free PMC article. Review.
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. ...Predictive biomarkers are needed to help inform clinicians to de-escalate or add therapy, including immune therapies, and to contribute to future clinical …
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. ...Predictive biomarkers …
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Isakoff MS, et al. J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304877 Free PMC article. Review.
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. ...Once promising agents are identified, an international infrastructure exists for clinical trials. Herein, biologic, preclinical, and clinical trial ef …
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. ...Once promising agents are ident …
Effects of rapamycin on osteosarcoma cell proliferation and apoptosis by inducing autophagy.
Yu WX, Lu C, Wang B, Ren XY, Xu K. Yu WX, et al. Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):915-921. doi: 10.26355/eurrev_202001_20076. Eur Rev Med Pharmacol Sci. 2020. PMID: 32016998 Free article.
OBJECTIVE: To investigate the influences of rapamycin on proliferation and apoptosis of human osteosarcoma MG-63 cells and the mechanisms of action. MATERIALS AND METHODS: The human osteosarcoma MG-63 cells were randomly divided into Control group, Rapamycin …
OBJECTIVE: To investigate the influences of rapamycin on proliferation and apoptosis of human osteosarcoma MG-63 cells and the mechan …
Osteosarcoma.
Gorlick R, Khanna C. Gorlick R, et al. J Bone Miner Res. 2010 Apr;25(4):683-91. doi: 10.1002/jbmr.77. J Bone Miner Res. 2010. PMID: 20205169 Free article.
Interestingly, several human genetic disorders and familial cancer syndromes, such as Li-Fraumeni syndrome, are linked to an increased risk of osteosarcoma. Association of these same genetic alterations and osteosarcoma risk have been confirmed in murine models. …
Interestingly, several human genetic disorders and familial cancer syndromes, such as Li-Fraumeni syndrome, are linked to an increased risk …
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Smeland S, et al. Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30685685 Free PMC article. Clinical Trial.
BACKGROUND: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare disease by fac …
BACKGROUND: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and A …
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Davis LE, et al. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23. J Clin Oncol. 2019. PMID: 31013172 Free PMC article. Clinical Trial.
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and r …
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including …
Radiation-induced sarcoma.
Patel SR. Patel SR. Curr Treat Options Oncol. 2000 Aug;1(3):258-61. doi: 10.1007/s11864-000-0037-6. Curr Treat Options Oncol. 2000. PMID: 12057168 Review.
The most common histologic subtypes are malignant fibrous histiocytoma (MFH) and osteosarcoma, although other histologies (eg, angiosarcoma, rhabdomyosarcoma) can occur. ...All low-grade tumors and high-grade tumors 5 cm or smaller should be treated with a margin-negative …
The most common histologic subtypes are malignant fibrous histiocytoma (MFH) and osteosarcoma, although other histologies (eg, angios …
Current questions in bone sarcomas.
Strauss SJ, Whelan JS. Strauss SJ, et al. Curr Opin Oncol. 2018 Jul;30(4):252-259. doi: 10.1097/CCO.0000000000000456. Curr Opin Oncol. 2018. PMID: 29782347 Review.
PURPOSE OF REVIEW: Osteosarcoma and Ewing sarcoma, the most common primary bone tumours in young people, are curable in most patients. ...This review addresses questions about current management and emerging therapeutic targets for patients with osteosarcoma, Ewing …
PURPOSE OF REVIEW: Osteosarcoma and Ewing sarcoma, the most common primary bone tumours in young people, are curable in most patients …
Cabozantinib as an emerging treatment for sarcoma.
Schöffski P, Blay JY, Ray-Coquard I. Schöffski P, et al. Curr Opin Oncol. 2020 Jul;32(4):321-331. doi: 10.1097/CCO.0000000000000644. Curr Opin Oncol. 2020. PMID: 32541320 Review.
Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development. Here we review the preclinical findings and clinical development of cabozantinib in …
Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are …
5,136 results